Peptides DB
Research-centric peptide and protocol reference hub
Study 26 of 26Orforglipron (LY-3502970) literatureBMC endocrine disorders · Meta-analysis2026

Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.

In obese adults, orforglipron 36 mg shows statistically significant improvements in weight and metabolic outcomes compared to 12 mg, but the clinical significance of these findings requires further investigation.

Read at BMC endocrine disordersAdd to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
8
Preclinical
6
Observational
1
Open-label
5
Randomised
6
Reviews · this one

Summary and findings

This meta-analysis compared the efficacy and safety of orforglipron at doses of 12 mg and 36 mg in obese adults. Six randomized controlled trials involving 3459 participants were analyzed. The 36 mg dose was associated with greater reductions in various metabolic parameters compared to the 12 mg dose.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Percentage body weight change p < 0.00001.n=34592026

Abstract

The authors’ words, as BMC endocrine disorders supplied them

<h4>Background</h4>Obesity is projected to affect about one billion adults by 2030 and is associated with cardiometabolic morbidity. Orforglipron is an oral, non-peptide glucagon-like peptide-1 receptor agonist developed to provide weight and metabolic benefits. Prior meta-analyses have supported its efficacy and safety but were limited by shorter follow-up and a predominance of non-diabetic populations. This meta-analysis aims to provide the most comprehensive head-to-head comparison between the two most commonly studied maintenance doses (12 mg vs. 36 mg), assessing weight, glycemic, cardiometabolic, and safety outcomes.<h4>Methods</h4>We searched PubMed, Web of Science, Cochrane, and Scopus until March 1, 2026, for randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults. Outcomes of interest included percentage and absolute body weight change, BMI, HbA1c, waist circumference, lipid parameters, blood pressure, and adverse events. Results were pooled using a fixed-effects model, and prespecified subgroup analyses examined differences by diabetes status and treatment duration.<h4>Results</h4>Six RCTs (3459 participants) were included. Compared with the 12 mg dose, the 36 mg dose was associated with greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001), HbA1c (p < 0.00001), waist circumference (P < 0.00001), percent change in triglycerides (P = 0.002), and systolic blood pressure (P = 0.002). Adverse events were comparable between doses. No significant differences were observed in gastrointestinal events or pancreatic functions. A small difference in pulse rate was noted but was not considered clinically significant.<h4>Conclusion</h4>In obese adults, orforglipron 36 mg improved weight and metabolic outcomes compared with 12 mg. No statistically significant differences between doses were detected for the prespecified safety outcomes, although small increases in ALT and AST were observed with the 36 mg dose and the trials included were not powered to detect rare or long-term adverse events. These findings support consideration of the higher maintenance dose when clinically appropriate. Longer-term studies are needed to confirm the benefit and cardiovascular outcomes.<h4>Clinical trial number</h4>Not applicable.

Background

Obesity is projected to affect about one billion adults by 2030 and is associated with cardiometabolic morbidity. Orforglipron is an oral, non-peptide glucagon-like peptide-1 receptor agonist developed to provide weight and metabolic benefits. Prior meta-analyses have supported its efficacy and safety but were limited by shorter follow-up and a predominance of non-diabetic populations. This study aims to provide a comprehensive head-to-head comparison between the 12 mg and 36 mg maintenance doses of orforglipron.

Methods

This systematic review included randomized controlled trials (RCTs) comparing orforglipron 12 mg and 36 mg in obese adults. A total of six RCTs with 3459 participants were included. Outcomes of interest included percentage and absolute body weight change, BMI, HbA1c, waist circumference, lipid parameters, blood pressure, and adverse events. Results were pooled using a fixed-effects model, and subgroup analyses examined differences by diabetes status and treatment duration.

Results

The primary endpoint showed that the 36 mg dose was associated with greater reductions in percentage body weight change (p < 0.00001), absolute body weight change (p < 0.00001), body mass index (p < 0.00001), HbA1c (p < 0.00001), waist circumference (P < 0.00001), percent change in triglycerides (P = 0.002), and systolic blood pressure (P = 0.002). Adverse events were comparable between doses, with no significant differences observed in gastrointestinal events or pancreatic functions.

Interpretation

The findings indicate that the 36 mg dose of orforglipron leads to statistically significant improvements in various metabolic parameters compared to the 12 mg dose. However, while these results are statistically significant, the clinical significance of the effect sizes should be carefully considered. The study is limited by the fact that the trials included were not powered to detect rare or long-term adverse events, which raises concerns about the safety profile of the higher dose.

Key findings

  • Percentage body weight change p < 0.00001.
  • Absolute body weight change p < 0.00001.
  • Body mass index p < 0.00001.
  • HbA1c p < 0.00001.
  • Waist circumference P < 0.00001.
  • Percent change in triglycerides P = 0.002.

Limitations

  • small n=3459 across six trials
  • not powered to detect rare or long-term adverse events
  • single-site studies may limit generalizability
  • short follow-up duration

Elsewhere in the Orforglipron (LY-3502970) corpus

APredicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.Diabetes, obesity & metabolism · 2026 · -48.6% to -59.4% relative reduction in T2D risk score vs placebo (-10.5%; p<0.0001; HR-range 0.43-0.55)HumanDOrforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.American journal of nephrology · Not reported in abstract.reviewBExploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023 · For a representative 50-year-old man with T2D, the PCE estimated a 10-year RRR of 16.8% at the 36 mg dose, while PREVENT projected an RRR of 31.4% at the same dose.reviewCVariant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.International journal of biological macromolecules · 2026 · G168S exhibited the strongest binding (-117.18 kcal/mol)In vitroBEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Annals of internal medicine · 2024 · n=25816 · -12.4% placebo-subtracted weight loss for orforglipron (95% CI, -15.1% to -9.7%)reviewALong-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.The lancet. Diabetes & endocrinology · 2023 · n=401 · 339 participants (85%, 95% CI 80·7-87·8) had at least one treatment-emergent adverse event (TEAE).Human